David Drobne

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy

Filip Baert, David Drobne, Ann Gils et al. · Clinical Gastroenterology and Hepatology · 2014 · 134 citations · Full text

Trough Levels, Autoimmune Disease, Allergy +9

Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease

David Drobne, Peter Bossuyt, Christine Breynaert et al. · Clinical Gastroenterology and Hepatology · 2014 · 131 citations

Inflammation, Chronic Inflammatory Diseases, Co-treatment Does +8

Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy

Uri Kopylov, Jurij Hanžel, Claire Liefferinckx et al. · Alimentary Pharmacology & Therapeutics · 2020 · 78 citations · Full text

Down‐regulation of micro<scp>RNA</scp>s of the <i>miR‐200</i> family and up‐regulation of Snail and Slug in inflammatory bowel diseases — hallmark of epithelial−mesenchymal transition

Nina Zidar, Emanuela Boštjančič, Miha Jerala et al. · Journal of Cellular and Molecular Medicine · 2016 · 65 citations · Full text

Endoscopic Postoperative Recurrence in Crohn’s Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study

Henit Yanai, A Kagramanova, O. V. Knyazev et al. · Journal of Crohn s and Colitis · 2022 · 59 citations · Full text